Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease

Journal of Infectious Diseases

Volumn 188, Issue 4, 2003, Pages 541-548

  Alexander, Christopher S ^a   Asselin, Jérôme J ^a   Ting, Lillian S L ^a   Montaner, Julio S G ^a   Hogg, Robert S ^a   Yip, Benita ^a   O'Shaughnessy, Michael V ^a   Harrigan, P Richard ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DELAVIRDINE; EFAVIRENZ; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZORBAX;

ADULT; ARTICLE; CANADA; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PREDICTION; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; PATIENT COMPLIANCE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0041941506     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/376835     Document Type: Article

References (35)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13:F35-43.
3. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-8.
4. Fletcher CV. Pharmacologic considerations for therapeutic success with antiretroviral agents. Ann Pharmacother 1999; 33:989-95.
5. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000; 283:2417-26.
6. Grub S, Bryson H, Goggin T, Ludin E, Jorga K. The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol 2001; 57:115-21.
7. de Maat MM, Hoetelmans RM, Mathot RA, et al. Drug interaction between St John's wort and nevirapine. AIDS 2001; 15:420-1.
8. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34:234-8.
9. Burger DM, Hoetelmans RM, Hugen PW, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther 1998; 3:215-20.
10. Gieschke R, Fotteler B, Buss N, Steimer JL. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin Pharmacokinet 1999; 37:75-86
11. Reijers MH, Weigel HM, Hart AA, et al. Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study. AIDS 2000; 14:59-67.
12. Veldkamp AI, Weverling GJ, Lange JM, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001; 15:1089-95.
13. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buslin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 71-5.
14. Chan S, Zhang M, Pithavala Y, Kerr B, Knowles M. Potential early predictors of long term virologic response to nelfinavir mesylate (Viracept): plasma drug concentration, baseline viral load and initial 4-week change in viral load [abstract A-11]. In: Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 1998:4.
15. Hoetelmans RMW, Meenhorst PL, Mulder JW, et al. Plasma concentrations of saquinavir determine HIV-1 RNA response over a 48-week period [abstract 42261]. In: Program and abstracts of the 12th World AIDS Conference (Geneva, Switzerland). Bologna: Monduzzi Editore, 1998:825.
16. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15:1181-3.
17. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
18. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple combination therapy is predictive of mortality, at baseline and after one year of follow-up. AIDS 2002; 16:1051-8.
19. Wagner JH, Justice AC, Chesney M, Sinclair G, Weissman S, Rodriguez-Barradas M, VACS 3 Project Team. Patient- and provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence. J Clin Epidemiol 2001; 54 (Suppl 1):S91-8.
20. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000; 23:360-1.
21. Montaner JSG, Hogg R, Yip B, Wood E, Harrigan R, O'Shaughnessy M. Further characterizing the determinants of disease progression among HIV-1 infected patients initiating triple drug therapy. In: Program and abstracts of the 1st IAS Conference on HIV Pathogenesis and Treatment (Buenos Aires, Argentina). Stockholm: International AIDS Society, 2001:323.
22. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001; 33: 1417-23.
23. Wagner GJ, Rabkin JG. Measuring medication adherence: are missed doses reported more accurately than perfect adherence? AIDS Care 2000; 12:405-8.
24. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Montaner JS. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286: 2568-77.
25. Kaletra product information. North Chicago, IL: Abbott Laboratories; 2000.
26. Viramune product monograph. Columbus, OH: Roxane Laboratories; 2000.
27. Sustiva product monograph. Mississauga, Ont.: Dupont Pharma; 1999.
28. Norvir product monograph. North Chicago, IL: Abbott Laboratories; 2000.
29. Rescriptor product monograph. Mississauga, Ont.: Pharmacia and Upjohn; 1998.
30. Viracept product monograph. La Jolla, CA: Agouron Pharmaceuticals; 2000.
31. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34:187-202.
32. Turner ML, Acosta EP. Long-term stability of nelfinavir mesylate in human plasma. Clin Chem 2000;46:2019-20.
33. Motessori V, Heath KV, Yip B, Hogg RS, O'Shaughnessy MVO, Montaner SJG. Predictors of adherence with triple combination antiretroviral therapy (abstract 72). In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria: Foundation for Retrovirology and Human Health, 2000:89.
34. Wood E, Hogg R, Yip B, O'Shaughnessy MV, Montaner, JS. The impact of baseline CD4 T-cell count and adherence on rates of disease progression among HIV-infected patients initiating triple drug antiretroviral therapy [abstract 465-M]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria: Foundation for Retrovirology and Human Health, 2002:228.
35. Baxter JD, Merigan TC, Wentworth DN, et al. Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy. AIDS 2002; 16:1131-38.